Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SW-BIC-213 Heterologous Booster vs Pfizer vs Sinopharm in COVID-19 Vaccinated Adults
NCT05686161Phase 3Unknown
- Sponsor
- Stemirna Therapeutics
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SW-BIC-213 in coronavirus disease 2019 (COVID-19), sponsored by Stemirna Therapeutics. Status: unknown.
02
Drugs
SW-BIC-213
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05686161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05686161.